• Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • Data collected included the type of malignancy, chemotherapy regimens, and patient comorbidities. (jhoponline.com)
  • Recommendations from the NCCN and from the American Society of Clinical Oncology and the published literature regarding regimens associated with febrile neutropenia were used to determine appropriate therapy. (jhoponline.com)
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. (drugs.com)
  • The FLT3 inhibitors sorafenib, midostaurin, quizartinib and gilteritinib have been tested in monotherapy in several settings including refractory or relapsed AML (R/R AML), post-transplant maintenance as well as in combination with intensive chemotherapy (ICT) or non-intensity regimens. (dovepress.com)
  • The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. (herceptin.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • On September 9, 2022, FDA approved ROLVEDON™ (formerly known as Rolontis)(eflapegrastim-xnst) injection indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. (wikipedia.org)
  • A recent systematic review of the literature reported on randomized controlled trials and nonrandomized studies on the use of granulocyte colony-stimulating factor therapies (G-CSFs) to reduce the incidence of febrile neutropenia, and found that short- and long-acting therapies, when dosed according to guidelines, have little difference in their efficacy. (centerforbiosimilars.com)
  • Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. (jnccn.org)
  • 3 . Aapro MS et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. (trillium.de)
  • Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage mylodysplasia. (jalsg.jp)
  • Prophylactic antibiotics are often used in pediatric patients for the treatment of acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (ALL), and for those undergoing hematopoietic stem cell transplant (HSCT) who are receiving intensive chemotherapy. (jhoponline.com)
  • 3 Patients receiving intensive chemotherapy for AML or ALL and those undergoing HSCT have an increased risk for serious bacterial infections. (jhoponline.com)
  • Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. (trillium.de)
  • Although various guidelines for the management of fever and neutropenia have been developed, none are dedicated to children. (crimsonpublishers.com)
  • Febrile Neutropenia (FN) is a common complication of chemotherapy and a main cause of morbidity and mortality in cancer patients[ 1 ]. (ijpsonline.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy - evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). (trillium.de)
  • Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. (trillium.de)
  • Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: A systematic review. (trillium.de)
  • Adults who had a diagnosis of cancer and received G-CSFs as prophylaxis for febrile neutropenia were included in this analysis. (jhoponline.com)
  • The results demonstrated that 47.22% and 8.2%, respectively, of G-CSF administrations did not have an indication supported by guideline recommendations for administering filgrastim and pegfilgrastim as prophylaxis for febrile neutropenia. (jhoponline.com)
  • Alexander, D., Messinger, Y., Safety of Transdermal Scopolamine in Pediatric Patients for Chemotherapy-induced Nausea and Vomiting , Journal of Clinical Oncology. (hennepinhealthcare.org)
  • These areas include a Cochrane systematic review of the treatment of chemotherapy-induced nausea and vomiting, the treatment of constipation, and risk stratification in nephropathy. (york.ac.uk)
  • Cytotoxic chemotherapy often induces febrile neutropenia and may lead to serious complications including mortality. (ijpsonline.com)
  • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. (trillium.de)
  • Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. (trillium.de)
  • However, because secondary analyses suggested that serious adverse events and all-cause mortality occurred more often in patients who are persistantly febrile the short treatment group, we recommend vigilance for non-susceptible pathogens and early resumption of empirical therapy in patients who are deteriorating. (amsterdamumc.org)
  • 2,3 Kuderer and colleagues estimated a 9.5% (95% confidence interval, 9.5%-9.8%) direct mortality risk for patients with cancer who were hospitalized with febrile neutropenia.2 Suboptimal chemotherapy treatment may affect patient outcomes and the overall efficacy of cancer management. (jhoponline.com)
  • Dec 27, 2018 Spectrum announced its submission of the Biologics License Application to the FDA for Rolontis (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia based on 643 early-stage breast cancer patients. (wikipedia.org)
  • Febrile neutropenia is a common and serious complication of cancer chemotherapy. (ijpsonline.com)
  • The objective of this protocol was to develop a reference tool for the evaluation and management of febrile neutropenia in a fourth-level cancer hospital in Ecuador and provide a guideline for a timely and adequate care of cancer patients. (ijpsonline.com)
  • This document compiles updated information available on the definition, risk factors, evaluation methods, treatment and special situations in cancer patients with febrile neutropenia. (ijpsonline.com)
  • Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. (jnccn.org)
  • Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. (trillium.de)
  • Colony-stimulating factors for febrile neutropenia during cancer therapy. (trillium.de)
  • Filling in the gaps: Reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. (trillium.de)
  • The purpose of this study is to determine whether short-course antibiotic therapy is safe and effective for the treatment of cancer patients with febrile neutropenia. (druglib.com)
  • Researchers have found that patients who have breast cancer who undergo treatment with taxanes show a pattern of clinically meaningful, persistent sensory and motor symptoms associated with chemotherapy-induced peripheral neuropathy, according to new findings presented by Trivedi et al at the 2023. (ascopost.com)
  • A FAB/LMB96 group C chemotherapy regimen for aggressive and high-risk cancer was administered with a marked improvement in clinical symptoms. (hindawi.com)
  • One of the major side effects of cancer chemotherapy is myelosuppression leading to an obligate period of neutropenia. (biomedgrid.com)
  • Chemotherapy treatments for cancer are well-‐ known to be associated with a depletion of white blood cells, in particular neutrophils, causing a condition known as chemotherapy-‐ induced neutropenia (CIN), as described in Figure 1. (biomedgrid.com)
  • Neutropenia is a serious adverse effect frequently associated with cancer chemotherapy (1,7). (biomedgrid.com)
  • Cancer patients undergoing chemotherapy may be particularly vulnerable to medical errors, as their care often requires use of high-risk medications and must be closely coordinated between multiple physicians. (ahrq.gov)
  • Working in the Cancer Center, a collaborative team-based setting, I help to review and coordinate chemotherapy and supportive care medications as well as provide patient counseling and side effect management. (hennepinhealthcare.org)
  • Nusseibeh E, Weber L , Won K, Reidt, S, Chart Review of Predisposing Factors to Cisplatin-Induced Nephrotoxicity in Patients with Cancer , Journal of Hematology Oncology Pharmacy. (hennepinhealthcare.org)
  • Guideline recommendations for the prevention and/or treatment of patients with febrile neutropenia have been published by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Infectious Diseases Society of America (IDSA). (jhoponline.com)
  • He is the lead of the PICNICC collaboration, "Predicting Infectious ComplicatioNs In Children with Cancer" which was formed by engaging international clinical and methodological experts, parent representatives and healthcare researchers to investigate primarily the patterns of risk in febrile neutropenia. (york.ac.uk)
  • In addition to the work in febrile neutropenia, he has undertaken many systematic reviews assessing the quality of evidence underlying interventions to ameliorate the side effects of cancer treatments in childhood. (york.ac.uk)
  • In contrast to medical science that seeks a cure for cancer, nursing science attempts to reduce adverse effects from chemotherapy and stress to improve the quality of life during and after treatment. (luriechildrens.org)
  • TRODELVY ® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. (trodelvyhcp.com)
  • KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. (keytrudahcp.com)
  • This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice. (jnccn.org)
  • BT-ON014 trade name] treatment should only be initiated by a health care provider experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a health care provider only. (who.int)
  • Neutrophils play a vital role in protecting against infection, so the duration and severity of neutropenia directly correlate with the total incidence of all infections, including those that are life threatening. (medscape.com)
  • [ 3 ] Major causes of acquired neutropenia are infection, drugs (through direct toxicity or immune effects), and autoimmunity. (medscape.com)
  • Tuberculosis (see the image below) is one type of infection that may cause neutropenia. (medscape.com)
  • However, neutropenia is detected in these patients only after the onset of infection limiting the efficacy of these therapeutic interventions. (biomedgrid.com)
  • With the increasing use of myelo-suppressive agents in the treatment of neoplastic and nonneoplastic diseases, the increased rate of infection in patients with neutropenia has been clearly established 3. (ukessays.com)
  • In outbreak investigations, asymptomatic infection has been reported in approximately 20% of children and adults (19,20). (cdc.gov)
  • Joint symptoms, more common in adults, may occur as the sole manifestation of infection. (cdc.gov)
  • Death before 30 days after neutrophil recovery occurred in five (3%) participants in the short treatment group: two due to progressive leukaemia, two due to candidaemia, and one due to Enterococcus faecium bacteraemia and drug-induced pneumonitis. (amsterdamumc.org)
  • Among the first line anti-TB drugs, INH, Rifampicin and Pyrazinamide are considered to be the most hepatotoxic drugs and cause drug induced hepatitis. (banglajol.info)
  • Anti-TB drug induced hepatitis usually occurs within 2 months after starting treatment. (banglajol.info)
  • This article reviews the incidence, risk factors, mechanism, diagnosis and management strategies of anti-TB drug induced hepatitis. (banglajol.info)
  • Neutropenia is a common dose-limiting toxicity of myelosuppressive chemotherapy and exposes patients to life-threatening infections and treatment delays. (jhoponline.com)
  • It is also crucial to assess the risk of serious complications in patients with febrile neutropenia, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization 2. (ukessays.com)
  • Current progress in the treatment of adult acute leukemia in Japan. (jalsg.jp)
  • Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. (jalsg.jp)
  • Assessment of the nutritional status and its influence on treatment outcome children with Acute Lymphoblastic Leukemia (ALL) before and after induction chemotherapy. (banglajol.info)
  • Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. (u-tokyo-hemat.com)
  • For palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. (nih.gov)
  • The patient developed an acute febrile illness in August 2012 during a 1-month vacation in New Mexico. (cdc.gov)
  • Furthermore, they can lead to delays and dose reductions in chemotherapy treatment, thereby potentially compromising the efficacy of chemotherapy and, consequently, patient outcome [ 10 ]. (hindawi.com)
  • This randomized, open-label, multicenter trial compared the efficacy and safety of Tasigna versus Gleevec in adult patients with newly diagnosed Ph+ CML in chronic phase(1). (salesandmarketingnetwork.com)
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. (drugs.com)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • Mikula J., Weber L. , Won K., Chemotherapy Toxicity Occurrence with Concomitant Antiretroviral Therapy in Patients with Lymphoma . (hennepinhealthcare.org)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • The duration and severity of neutropenia directly correlate with the total incidence of all infections and of those infections that are life threatening. (medscape.com)
  • The risk increases with the duration and severity of the neutropenia. (biomedgrid.com)
  • The complete results from a 5-year open-label extension study of Nplate in the adult chronic ITP setting show that Nplate increases and sustains platelet counts in these patients and that adverse event rates were consistent with those reported in previous studies," said Sean Harper, M.D., senior vice president, Global Development and Chief Medical Officer at Amgen. (amgen.com)
  • KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD⁠-⁠1) or the programmed death ligand 1 (PD⁠-⁠L1), blocking the PD⁠-⁠1/PD⁠-⁠L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. (keytrudahcp.com)
  • Serious adverse reactions (ARs) were reported in 49% of patients in the VENCLEXTA plus obinutuzumab arm, most often due to febrile neutropenia and pneumonia (5% each). (abbvie.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • Publications eligible for inclusion in the review involved adults with nonmyeloid malignancies receiving chemotherapy. (centerforbiosimilars.com)
  • Development timeline for Rolvedon: Sep 9, 2022 Spectrum announced FDA Approval of Rolvedon (eflapegrastim-xnst) Injection to Decrease the Incidence of Chemotherapy-Induced Neutropenia April 11, 2022 FDA announced acceptance of Spectrum's re-submission of its Rolontis Biologics License Application (BLA)to FDA. (wikipedia.org)
  • Pneumonitis rates for adult patients with cHL were similar in patients with and without prior thoracic radiation. (keytrudahcp.com)
  • Adult patients with cHL who developed pneumonitis received high-dose corticosteroids for a median duration of 10 days (range: 2 days-53 months). (keytrudahcp.com)
  • Adult patients with resected NSCLC who were treated with KEYTRUDA as adjuvant monotherapy and developed pneumonitis received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). (keytrudahcp.com)
  • A multicenter study in Argentina reported 515 episodes of FN in 346 patients, of which 77 % were secondary to chemotherapy. (ijpsonline.com)
  • All RTCs showed similar levels of dose reduction of chemotherapy or delays in anticancer treatment for short- and long-acting agents. (centerforbiosimilars.com)
  • Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool. (u-tokyo-hemat.com)
  • Repeated infections results in prolonged periods of hospitalisation, delay in treatment and chemotherapy dose reductions. (biomedgrid.com)
  • Where neutropenia is significant, it is associated with an increased risk of systemic infections that lead to sepsis and death (1,2,3,7,9). (biomedgrid.com)
  • longer durations of therapy may be required for deep seated infections or in cases of prolonged courses of chemotherapy or neutropenia. (medicines.org.uk)
  • They require prompt evaluation and hospital administration of broad-spectrum intravenous antibiotics, the aggressive approach has been universally recommended because approximately 60% of febrile neutron episodes are caused by bacterial infections (with or without bacteremia), a condition that was difficult to identify in many children [2,3]. (crimsonpublishers.com)
  • EMEND capsules in adults and pediatric patients 12 years of age and older: is 125 mg on Day 1 and 80 mg on Days 2 and 3. (nih.gov)
  • EMEND for oral suspension in pediatric patients 6 months to less than 12 years of age or pediatric and adult patients unable to swallow capsules: see dosing recommendations in Table 3 in the Full Prescribing Information. (nih.gov)
  • Use of KEYTRUDA in pediatric patients for these indications is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients. (keytrudahcp.com)
  • Patient safety in chemotherapy care-a review of the literature. (ahrq.gov)
  • See "Initial treatment of rheumatoid arthritis in adults" . (medilib.ir)
  • See "Major side effects of low-dose methotrexate" and "Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease" and "Methotrexate-induced lung injury" and "Initial treatment of rheumatoid arthritis in adults" and "Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy" . (medilib.ir)
  • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). (drugs.com)
  • People exposed to radiation may be divided into "low-risk" and "high-risk" susceptibility groups, based on degree of neutropenia and the presence of comorbidities. (msdmanuals.com)
  • The European Society for Medical Oncology (ESMO, 2016) reported an incidence of approximately 8 cases of FN per 1000 patients who received chemotherapy[ 1 ]. (ijpsonline.com)
  • Torma K., Weber LM , Won K., Appropriate Antibiotic Selection in Oncology Patients Admitted with Febrile Neutropenia , Poster Presentation at the American Society of Health-System Pharmacy Meeting, Anaheim, California December 2010. (hennepinhealthcare.org)
  • Bob is a Senior Clinical Academic at CRD, and an Honorary Consultant in Paediatric / Teenage-Young Adult Oncology at Leeds Children's Hospital. (york.ac.uk)
  • Patients never treated for their CLL have had to rely largely on chemotherapy as their initial treatment," said Michael Hallek , M.D., lead investigator of the CLL14 study, Department of Internal Medicine and Center of Integrated Oncology at the University Hospital Cologne in Germany , and Head of the German CLL Study Group. (abbvie.com)
  • EAST HANOVER, N.J., Feb. 19 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (salesandmarketingnetwork.com)
  • Tasigna has been approved in more than 80 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. (salesandmarketingnetwork.com)
  • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). (drugs.com)